Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Milan
Clinical trial register · Italy

Clinical Trials in Milan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6793 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:20 UTC
6793
Studies in scope
all four open statuses
4085
Recruiting now
open to new participants
1016
Lead sponsors
across recruiting studies
Top sites
Milan 14 Meldola 7 Bologna 6 Roma 6 Brescia 6

Trials with a site in Milan

14 of 6793 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Genmab
Phase 1
78
Bergamo, Milan, Pisa
2026-02-16
Recruiting
Genmab
Phase 3
660
Bologna, Catania, Meldola, Monza, Milan, Prato, Reggio Emilia
2025-11-28
Active, closed
Genmab
Phase 3
584
Brindisi, Milan, Ponderano, Roma, Torino
2025-02-07
Active, closed
Genmab
Phase 3
699
Ancona, Brescia, Cagliari, Meldola, Milan, Naples, Rome, Rozzano
2024-09-25
Active, closed
Genmab
Phase 3
621
Brescia, Cuneo, Milan, Naples, Roma, Rozzano
2024-06-25
Active, closed
Genmab
Phase 3
549
San Giovanni Rotondo, Milan, Turin, Aviano, Rome, Candiolo, Alessandria, Bari
2022-09-20
Active, closed
Genmab
Phase 3
483
Bari, Bergamo, Brescia, Meldola, Milan, Novara, Pavia, Ravenna
2021-01-13
Active, closed
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Genmab
Phase 1/2
194
Bologna, Torino, Ferrara, Meldola, Rome, Roma, Brescia, Milan
2020-11-25
Active, closed
Genmab
Phase 1/2
543
Bergamo, Bologna, Candiolo, Meldola, Milan, Pavia, Reggio Emilia
2020-11-03
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
Genmab
Phase 1/2
350
Brescia, Cuneo, Milan, Rozzano
2019-09-17
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
Genmab
Phase 1/2
666
Alessandria, Bologna, Candiolo, Meldola, Milan
2018-06-26
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Genmab
Phase 1/2
560
Milan
2018-05-02
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 November 2026. https://priyalifescience.com/clinical-trials-italy/city/milan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,793 studies in total at the last sync on 17 Nov 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Milan that also match the filters currently applied.

How many clinical trials are recruiting in Milan?

4 of the 14 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Milan), 14 studies
PhaseStudiesRecruitingShare
Phase 38257.1%
Phase 1/25135.7%
Phase 1117.1%

Most active sponsors

Lead sponsors with the most studies (Milan)
Lead sponsorStudiesRecruiting
Genmab144
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.